BeiGene (BGNE) Stock Forecast, Price Target & Predictions
BGNE Stock Forecast
BeiGene stock forecast is as follows: an average price target of $255.80 (represents a 31.48% upside from BGNE’s last price of $194.56) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
BGNE Price Target
BGNE Analyst Ratings
Buy
BeiGene Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 18, 2024 | Reni Benjamin | JMP Securities | - | - | 45.82% | 48.03% |
Aug 23, 2024 | Matthew Harrison | Morgan Stanley | - | - | 58.60% | 57.79% |
May 09, 2024 | Kelly Shi | Jefferies | - | - | 72.10% | 45.46% |
Jun 30, 2023 | Rebecca Liang | Bernstein | - | - | 9.83% | 0.74% |
Oct 13, 2022 | Michael Schmidt | Guggenheim | - | - | 35.49% | 5.37% |
10
BeiGene Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 3 |
Avg Price Target | - | $297.50 | $292.67 |
Last Closing Price | $194.56 | $194.56 | $194.56 |
Upside/Downside | -100.00% | 52.91% | 50.43% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 18, 2024 | Johnson Rice | Market Perform | Initialise | |
Sep 18, 2024 | JMP Securities | Market Outperform | Outperform | Initialise |
Sep 18, 2024 | JMP Securities | Market Outperform | Initialise | |
Aug 23, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Aug 08, 2024 | Citigroup | Buy | Buy | Hold |
Jul 22, 2024 | Jefferies | Buy | Buy | Hold |
May 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
May 09, 2024 | Jefferies | Buy | Buy | Hold |
Apr 08, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
Sep 21, 2023 | Citigroup | Buy | Buy | Hold |
10
BeiGene Financial Forecast
BeiGene Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $781.31M | $595.26M | $447.80M | $380.10M | $387.63M | $341.57M | $306.63M | $213.98M | $206.44M | $149.99M | $605.87M | $100.10M | $91.08M | $65.64M | $52.06M | $56.89M | $50.14M |
Avg Forecast | $1.37B | $1.29B | $1.27B | $1.24B | $1.21B | $1.16B | $1.12B | $1.07B | $1.04B | $983.26M | $810.34M | $670.09M | $637.01M | $596.75M | $501.07M | $444.20M | $388.17M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
High Forecast | $1.41B | $1.33B | $1.30B | $1.27B | $1.24B | $1.19B | $1.15B | $1.10B | $1.08B | $1.01B | $810.34M | $670.09M | $694.19M | $601.85M | $513.88M | $455.56M | $398.10M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
Low Forecast | $1.33B | $1.26B | $1.23B | $1.21B | $1.17B | $1.13B | $1.09B | $1.04B | $1.01B | $955.26M | $810.34M | $670.09M | $592.44M | $591.65M | $488.15M | $432.74M | $378.16M | $385.69M | $313.18M | $260.37M | $214.58M | $186.26M | $175.82M | $258.05M | $121.53M | $86.28M | $64.76M | $49.12M | $60.25M | $65.43M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 3 | 6 | 4 | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 1.19% | 1.01% | 0.98% | 1.01% | 1.09% | 1.18% | 1.00% | 1.11% | 0.85% | 2.35% | 0.82% | 1.06% | 1.01% | 1.06% | 0.94% | 0.77% |
Forecast
BeiGene EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 3 | 6 | 4 | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-133.97M | $-296.38M | $-371.26M | $-468.43M | $-422.16M | $-439.21M | $-443.10M | $-586.62M | $-420.90M | $-469.04M | $71.50M | $-474.24M | $-425.30M | $-328.81M | $-354.43M | $-373.02M | $-306.55M |
Avg Forecast | $-1.22B | $-1.15B | $-1.13B | $-1.11B | $-1.08B | $-1.04B | $-996.73M | $-955.58M | $-930.94M | $-876.56M | $-722.40M | $-545.09M | $-567.88M | $-531.99M | $-446.69M | $-495.54M | $-391.61M | $-343.69M | $-279.07M | $-450.49M | $-191.22M | $-165.98M | $-156.67M | $144.78M | $-108.30M | $-76.88M | $-57.71M | $-365.39M | $-53.69M | $-58.31M |
High Forecast | $-1.19B | $-1.12B | $-1.10B | $-1.08B | $-1.05B | $-1.01B | $-971.03M | $-930.94M | $-904.84M | $-851.60M | $-722.40M | $-436.07M | $-528.14M | $-527.44M | $-435.17M | $-396.43M | $-313.29M | $-343.69M | $-279.07M | $-360.39M | $-191.22M | $-165.98M | $-156.67M | $173.74M | $-108.30M | $-76.88M | $-57.71M | $-292.31M | $-53.69M | $-58.31M |
Low Forecast | $-1.25B | $-1.18B | $-1.16B | $-1.13B | $-1.10B | $-1.06B | $-1.02B | $-980.03M | $-965.74M | $-901.52M | $-722.40M | $-654.11M | $-618.86M | $-536.54M | $-458.12M | $-594.65M | $-469.94M | $-343.69M | $-279.07M | $-540.59M | $-191.22M | $-165.98M | $-156.67M | $115.83M | $-108.30M | $-76.88M | $-57.71M | $-438.47M | $-53.69M | $-58.31M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 0.66% | 0.75% | 1.20% | 1.23% | 1.57% | 0.98% | 3.07% | 2.54% | 2.99% | 0.49% | 4.38% | 5.53% | 5.70% | 0.97% | 6.95% | 5.26% |
Forecast
BeiGene Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 3 | 6 | 4 | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $215.41M | $-381.14M | $-348.43M | $-445.33M | $-557.56M | $-571.45M | $-434.27M | $-585.65M | $-413.86M | $-480.34M | $66.50M | $-472.75M | $-425.22M | $-335.20M | $-363.74M | $-388.06M | $-307.36M |
Avg Forecast | $110.78M | $55.02M | $40.80M | $14.53M | $-9.54M | $-31.41M | $-46.80M | $-95.55M | $-103.39M | $-117.97M | $-231.86M | $-599.93M | $-369.47M | $-358.46M | $-355.98M | $-545.39M | $-390.97M | $-409.29M | $-419.65M | $-495.81M | $-520.67M | $-492.12M | $-391.46M | $134.65M | $-442.85M | $-431.36M | $-500.01M | $-374.98M | $-502.59M | $-404.29M |
High Forecast | $114.47M | $56.85M | $42.16M | $15.02M | $-9.22M | $-30.36M | $-45.23M | $-92.35M | $3.63M | $-114.02M | $-224.08M | $-479.94M | $-115.85M | $-346.45M | $-344.05M | $-436.31M | $-312.78M | $-409.29M | $-419.65M | $-396.65M | $-520.67M | $-492.12M | $-391.46M | $161.58M | $-442.85M | $-431.36M | $-500.01M | $-299.99M | $-502.59M | $-404.29M |
Low Forecast | $107.07M | $53.18M | $39.44M | $14.04M | $-9.86M | $-32.46M | $-48.36M | $-98.73M | $-235.79M | $-121.89M | $-239.57M | $-719.92M | $-508.80M | $-370.39M | $-367.82M | $-654.47M | $-469.16M | $-409.29M | $-419.65M | $-594.97M | $-520.67M | $-492.12M | $-391.46M | $107.72M | $-442.85M | $-431.36M | $-500.01M | $-449.98M | $-502.59M | $-404.29M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.60% | 1.07% | 0.64% | 1.14% | 1.36% | 1.36% | 0.88% | 1.12% | 0.84% | 1.23% | 0.49% | 1.07% | 0.99% | 0.67% | 0.97% | 0.77% | 0.76% |
Forecast
BeiGene SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 3 | 6 | 4 | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $364.42M | $395.03M | $328.50M | $328.98M | $322.89M | $331.40M | $294.57M | $306.50M | $269.23M | $232.29M | $182.11M | $208.21M | $160.84M | $124.05M | $107.08M | $143.35M | $105.00M |
Avg Forecast | $1.43B | $1.35B | $1.32B | $1.29B | $1.26B | $1.21B | $1.16B | $1.12B | $1.09B | $1.02B | $843.71M | $406.94M | $663.25M | $621.33M | $521.70M | $369.95M | $204.61M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
High Forecast | $1.46B | $1.38B | $1.35B | $1.33B | $1.29B | $1.24B | $1.19B | $1.14B | $1.13B | $1.05B | $843.71M | $488.33M | $722.78M | $626.63M | $535.05M | $443.93M | $245.54M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
Low Forecast | $1.39B | $1.31B | $1.29B | $1.26B | $1.22B | $1.18B | $1.13B | $1.09B | $1.06B | $994.60M | $843.71M | $325.55M | $616.83M | $616.02M | $508.25M | $295.96M | $163.69M | $401.57M | $326.07M | $271.10M | $223.42M | $193.93M | $183.06M | $268.68M | $126.53M | $89.83M | $67.43M | $51.14M | $62.73M | $68.13M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.76% | 0.89% | 1.61% | 0.80% | 1.02% | 1.09% | 1.37% | 1.39% | 1.27% | 0.68% | 1.65% | 1.79% | 1.84% | 2.09% | 2.29% | 1.54% |
Forecast
BeiGene EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 3 | 6 | 4 | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 7 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.58 | $-3.64 | $-3.34 | $-4.29 | $-5.39 | $-5.56 | $-4.24 | $-6.16 | $-4.68 | $-5.20 | $0.78 | $-5.20 | $-4.81 | $-4.29 | $-4.70 | $-6.37 | $-5.07 |
Avg Forecast | $1.05 | $0.52 | $0.39 | $0.14 | $-0.09 | $-0.30 | $-0.44 | $-0.90 | $-0.98 | $-1.11 | $-2.19 | $-3.09 | $-3.49 | $-3.38 | $-3.36 | $-3.66 | $-4.64 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
High Forecast | $1.08 | $0.54 | $0.40 | $0.14 | $-0.09 | $-0.29 | $-0.43 | $-0.87 | $0.03 | $-1.08 | $-2.12 | $-2.99 | $-1.09 | $-3.27 | $-3.25 | $-3.54 | $-4.48 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
Low Forecast | $1.01 | $0.50 | $0.37 | $0.13 | $-0.09 | $-0.31 | $-0.46 | $-0.93 | $-2.23 | $-1.15 | $-2.26 | $-3.20 | $-4.80 | $-3.50 | $-3.47 | $-3.79 | $-4.79 | $-3.91 | $-4.01 | $-4.12 | $-4.97 | $-4.70 | $-3.74 | $-1.90 | $-4.23 | $-4.12 | $-4.78 | $-4.85 | $-4.80 | $-3.86 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.47% | 1.08% | 0.91% | 0.93% | 1.38% | 1.39% | 1.03% | 1.24% | 1.00% | 1.39% | -0.41% | 1.23% | 1.17% | 0.90% | 0.97% | 1.33% | 1.31% |
Forecast
BeiGene Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IMAB | I-Mab | - | - | 3545.83% | Buy |
APLS | Apellis Pharmaceuticals | - | - | 168.47% | Buy |
ARWR | Arrowhead Pharmaceuticals | - | - | 148.25% | Buy |
LEGN | Legend Biotech | - | - | 108.03% | Buy |
IMVT | Immunovant | - | - | 61.38% | Buy |
BMRN | BioMarin Pharmaceutical | - | - | 60.28% | Buy |
ASND | Ascendis Pharma | - | - | 55.10% | Buy |
IONS | Ionis Pharmaceuticals | - | - | 52.27% | Buy |
AKRO | Akero Therapeutics | - | - | 47.44% | Buy |
PCVX | Vaxcyte | - | - | 40.29% | Buy |
BGNE | BeiGene | - | - | 31.48% | Buy |
INCY | Incyte | - | - | 20.13% | Buy |
TVTX | Travere Therapeutics | - | - | 19.11% | Buy |
BPMC | Blueprint Medicines | - | - | 13.55% | Buy |
KRYS | Krystal Biotech | - | - | 4.78% | Buy |
RXDX | Prometheus Biosciences | - | - | -30.69% | Buy |